Skip to Content

'
Vicente Valero, M.D., F.A.C.P.

Present Title & Affiliation

Primary Appointment

Chairman Ad Interim, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor of Medicine, Department of Breast Medical Oncology, Division of Cancer Medicine, UTMDACC, Houston, TX
Clinical Director, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Valero has been with The University of Texas M. D. Anderson Cancer Center since June 1991, obtaining his M.D. from the Universidad Autonoma de Nuevo Leon, Facultad de Medicine, in 1980. Postgraduate training in Internal Medicine was completed at St. Elizabeth Hospital in Youngstown, Ohio, and Northeastern Ohio University College of Medicine in Rootstown, Ohio. Fellowships in Hematology-Medical Oncology were completed at the University of Cincinnati, Ohio, and at The University of Texas Medical Branch in Galveston, Texas. Board certifications include the American Board of Internal Medicine, the American Board of Medical Oncology, and the American Board of Hematology.

Publications include over 150 published articles in peer-reviewed journals, editorials and invited articles, 13 book chapters, and over 100 abstracts. He is an actively involved teacher in the Medical Oncology Continuing Clinic for Fellows and medical oncology and internal medicine residents at Lyndon B. Johnson General Hospital and The University of Texas M. D. Anderson Cancer Center, where he was honored as the Division of Medicine Teacher of the Year for the 1993-1994 and 1996-1997 academic years, and the Educator of the Month for December 2003. He is the primary investigator for several ongoing funded research protocols, and as an acknowledged leader in his fields of interest, he is a popular and much sought after speaker for local, national, and international presentations, and has given over 250 presentations, maintaining his belief that sharing all facets of the knowledge of breast cancer with other treating physicians and healthcare providers and educating the public about this disease may translate to improvement in its prevention, early detection, and treatment.

Research Interests

Dr. Valero utilizes a multidisciplinary approach to the treatment of breast cancer. His research interests include breast neoplasms, unusual histologies, new drug development, minority groups, and clinical trials with angiogenesis. More specifically, his primary focus is in the area of Her-2 neu amplified and ER+ HER-2 normal early, as well as metastatic breast cancer and novel biological agents, the management of patients with locally advanced breast cancer utilizing new biological agents and gene profiling, and clinical research targeting minority populations.

Education & Training

Degree-Granting Education

1980 Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Monterrey, Nuevo Leon, Mexico, MD, Medicine

Postgraduate Training

7/1987-6/1988 Fellow, Hematology-Medical Oncology, Hematology-Medical Oncology, University of Texas Medical Branch, Department of Medicine, Galveston, TX, Frank H. Gardner MD
7/1985-6/1987 Fellow, Hematology-Medical Oncology, Hematology-Medical Oncology, University of Cincinnati Medical Center and Veterans Administration Hospital, Cincinnati, OH, Orlando Martelo MD
7/1982-6/1985 Internal Medicine: Resident, Internal Medicine, Saint Elizabeth Hospital Medical Center; Northeastern Ohio University College of Medicine, Youngstown; Rootstown, OH, Charles Wilkins MD

Experience/Service

Academic Appointments

Deputy Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-9/2012

Selected Publications

Peer-Reviewed Original Research Articles

1. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. e-Pub 3/2014. PMID: 24677057.
2. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol. e-Pub 3/2014. PMID: 24669015.
3. de Melo Gagliato D, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M. Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. J Clin Oncol. e-Pub 1/2014. PMID: 24470007.
4. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One 9(1):e83113, 2014. e-Pub 1/2014. PMCID: PMC3885405.
5. Lynch SP, Lei X, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, Hortobágyi GN, Gonzalez-Angulo AM, Valero V. Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence. Oncologist 18(11):1167-73, 2013. e-Pub 10/2013. PMID: 24136008.
6. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. J Clin Oncol 27(19):3185-91, 7/2009. e-Pub 4/2009. PMCID: PMC2716940.
7. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast Cancer Metastasis: Challenges and Opportunities. Cancer Res 69(12):4951-3, 6/2009. e-Pub 5/2009. PMID: 19470768.
8. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-24, 5/2009. e-Pub 5/2009. PMCID: PMC2737191.
9. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 113(9):2422-30, 11/2008. PMID: 18785255.
10. Brewster A, Hortobagyi GN, Broglio RK, Kau S, Santa-Maria CA, Arun B, Buzdar A, Booser D, Valero V, Bondy M, Esteva F. Residual Risk of Breast Cancer Recurrence 5 years After Adjuvant Therapy. J Natl Cancer Inst 100(16):1-5, 2008. e-Pub 2/2008. PMID: 18695137.
11. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25(31):4952-60, 11/2007. PMID: 17971593.
12. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13:4943-4948, 8/2007. PMID: 17699874.
13. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Jr., Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203-11, 3/2007. PMID: 17329190.
14. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with Paclitaxel and Fluorouracil, Doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24(26):4236-44, 9/2006. PMID: 16896004.
15. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 24:2113-22, 5/2006. PMID: 16648513.
16. Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 17:605-13, 4/2006. PMID: 16469754.
17. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304-11, 12/2005. PMID: 16361629.
18. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-6, 11/2005. PMID: 16258084.

Grant & Contract Support

Title: A clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer
Funding Source: NSABP
Role: Principal Investigator
Duration: 10/1/2008 - 1/31/2013
 
Title: Population Health and Health Disparities program
Funding Source: NIH/NCI
Role: Internal Advisory Board
Principal Investigator: Lovell A Jones, PhD

Last updated: 2/21/2014